Skip to main content

Table 1 Baseline characteristics and medication of SLE patients (n = 34) and healthy controls (HC, n = 18) included in the study.

From: Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus

  SLE patients HC P-value
Total number 34 18  
Women/men 28/6 15/3 ns
Age (years, mean ± SD) 41 ± 14 35 ± 11 ns
SLEDAI (median (range)) 4 (0 to 17)   
C3, g/l (median, range) 0.82 (0.37 to 1.45)   
C4, g/l (median, range) 0.21 (0.04 to 0.30)   
Anti-dsDNA, E/ml (median, range) 165 (4 to 1,000)   
Treatment, n   18  
   None 4   
   Glucocorticoids, n 23   
    median dose (range), dose (mg/day) 5 (3.75 to 60)   
Immunosupressive/immunmodulating, n    
   Hydroxychloroquine 17   
    median dose (range), users (mg/day) 400 (200 to 600)   
   Methotrexate 2   
    median dose (range), users (mg/week) 15 (5 to 25)   
   Azathioprine 12   
    median dose (range), users (mg/day) 112.5 (50 to 150)   
   MMF 4   
    median dose (range), users (mg/day) 2,500 (1,000 to 3,000)   
  1. SLEDAI: systemic lupus erythematosus disease activity index, MMF: mycophenolate mofetil.